POLA Orbis saw the highest growth of 99% in patent filings in March and 132% in grants in February in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 66% and grants by 74%. GlobalData’s DataBook provides a comprehensive analysis of POLA Orbis’s patent filings and grants. Buy the databook here.
POLA Orbis has been focused on protecting inventions in Japan(JP) with 16 publications in Q1 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 100% filings and 67% grants. The Japan(JP), European Patent Office(EPO), Canada(CA), and China(CN) patent Office are among the top ten patent offices where POLA Orbis is filings its patents. Among the top granted patent authorities, POLA Orbis has 67% of its grants in Japan(JP), 11% in European Patent Office(EPO) and 11% in Canada(CA).
Kao could be the strongest competitor for POLA Orbis
Patents related to rare diseases and healthtech lead POLA Orbis's portfolio
POLA Orbis has the highest number of patents in rare diseases followed by, healthtech and nanomedicine. For rare diseases, nearly 60% of patents were filed and 20% of patents were granted in Q1 2024.
Skincare related patents lead POLA Orbis portfolio followed by cosmetics & toiletries, and make-up
POLA Orbis has highest number of patents in skincare followed by cosmetics & toiletries, make-up, suncare, and diagnostic imaging. For skincare, nearly 44% of patents were filed and 31% of patents were granted in Q1 2024.
For comprehensive analysis of POLA Orbis's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.